{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:43:25Z","timestamp":1792417405546,"version":"4.4.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T00:00:00Z","timestamp":1792368000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1007\/s10072-026-09459-6","type":"journal-article","created":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T01:09:59Z","timestamp":1792372199000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of tolebrutinib in multiple sclerosis: a systematic review and meta-analysis"],"prefix":"10.1007","volume":"47","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-4688-7595","authenticated-orcid":false,"given":"Nada","family":"Mosad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-0343-8365","authenticated-orcid":false,"given":"Yara","family":"Roshdy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-3719-2902","authenticated-orcid":false,"given":"Tasbih","family":"Emad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-6161-0783","authenticated-orcid":false,"given":"Ahmed","family":"Harb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0630-6601","authenticated-orcid":false,"given":"Dina Essam","family":"Abo-elnour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4929-8274","authenticated-orcid":false,"given":"Yasein Fadel","family":"Awadalla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7388-1706","authenticated-orcid":false,"given":"Woroud","family":"AL Fauomi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1254-4289","authenticated-orcid":false,"given":"Asmaa Zakria","family":"Alnajjar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,19]]},"reference":[{"issue":"1","key":"9459_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41572-018-0041-4","volume":"4","author":"M Filippi","year":"2018","unstructured":"Filippi M, Bar-Or A, Piehl F, Preziosa P, Solari A, Vukusic S et al (2018) Multiple sclerosis. Nat Rev Dis Primers 4(1):43. https:\/\/doi.org\/10.1038\/s41572-018-0041-4","journal-title":"Nat Rev Dis Primers"},{"key":"9459_CR2","doi-asserted-by":"publisher","unstructured":"Joshua AM, Tiwari A, Kumari N, Pai S. Multiple Sclerosis. In: Joshua AM, editor. Physiotherapy for Adult Neurological Conditions [Internet]. Singapore: Springer Nature; 2022 [cited 2026 Sep 4]. p. 563\u2013601. Located at: Springer Link. Available from: https:\/\/doi.org\/10.1007\/978-981-19-0209-3_9","DOI":"10.1007\/978-981-19-0209-3_9"},{"issue":"14","key":"9459_CR3","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1177\/1352458520970841","volume":"26","author":"C Walton","year":"2020","unstructured":"Walton C, King R, Rechtman L, Kaye W, Leray E, Marrie RA et al (2020) Rising prevalence of multiple sclerosis worldwide: insights from the Atlas of MS, third edition. Mult Scler J 26(14):1816\u201321. https:\/\/doi.org\/10.1177\/1352458520970841","journal-title":"Mult Scler J"},{"issue":"9","key":"9459_CR4","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a028928","volume":"8","author":"S Klineova","year":"2018","unstructured":"Klineova S, Lublin FD (2018) Clinical Course of Multiple Sclerosis. Cold Spring Harb Perspect Med 8(9):a028928. https:\/\/doi.org\/10.1101\/cshperspect.a028928","journal-title":"Cold Spring Harb Perspect Med"},{"issue":"4","key":"9459_CR5","doi-asserted-by":"publisher","first-page":"264","DOI":"10.4103\/0972-2327.58283","volume":"12","author":"D Ontaneda","year":"2009","unstructured":"Ontaneda D, Rae-Grant AD (2009) Management of acute exacerbations in multiple sclerosis. Ann Indian Acad Neurol 12(4):264\u201372. https:\/\/doi.org\/10.4103\/0972-2327.58283","journal-title":"Ann Indian Acad Neurol"},{"issue":"7","key":"9459_CR6","doi-asserted-by":"publisher","first-page":"545","DOI":"10.12998\/wjcc.v3.i7.545","volume":"3","author":"A Gajofatto","year":"2015","unstructured":"Gajofatto A, Benedetti MD (2015) Treatment strategies for multiple sclerosis: when to start, when to change, when to stop? World J Clin Cases 3(7):545\u201355. https:\/\/doi.org\/10.12998\/wjcc.v3.i7.545","journal-title":"World J Clin Cases"},{"issue":"Suppl 3","key":"9459_CR7","doi-asserted-by":"publisher","first-page":"iii3","DOI":"10.1007\/s00415-005-2010-6","volume":"252","author":"F Lublin","year":"2005","unstructured":"Lublin F (2005) History of modern multiple sclerosis therapy. J Neurol 252(Suppl 3):iii3\u20139. https:\/\/doi.org\/10.1007\/s00415-005-2010-6","journal-title":"J Neurol"},{"issue":"1","key":"9459_CR8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/s13311-012-0160-7","volume":"10","author":"R Berkovich","year":"2013","unstructured":"Berkovich R (2013) Treatment of acute relapses in multiple sclerosis. Neurotherapeutics 10(1):97\u2013105. https:\/\/doi.org\/10.1007\/s13311-012-0160-7","journal-title":"Neurotherapeutics"},{"issue":"1","key":"9459_CR9","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9010012","volume":"9","author":"G Jalkh","year":"2020","unstructured":"Jalkh G, Abi Nahed R, Macaron G, Rensel M (2020) Safety of newer disease modifying therapies in multiple sclerosis. Vaccines (Basel) 9(1):12. https:\/\/doi.org\/10.3390\/vaccines9010012","journal-title":"Vaccines (Basel)"},{"key":"9459_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/ph16030400","author":"A Najmi","year":"2023","unstructured":"Najmi A, Thangavel N, Mohanan AT, Qadri M, Albratty M, Ashraf SE et al (2023) Structural complementarity of Bruton\u2019s tyrosine kinase and its inhibitors for implication in B-cell malignancies and autoimmune diseases. Pharmaceuticals (Basel). https:\/\/doi.org\/10.3390\/ph16030400","journal-title":"Pharmaceuticals (Basel)"},{"issue":"6","key":"9459_CR11","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1016\/s0006-2952(98)00122-1","volume":"56","author":"FM Uckun","year":"1998","unstructured":"Uckun FM (1998) Bruton\u2019s tyrosine kinase (BTK) as a dual-function regulator of apoptosis. Biochem Pharmacol 56(6):683\u201391. https:\/\/doi.org\/10.1016\/s0006-2952(98)00122-1","journal-title":"Biochem Pharmacol"},{"key":"9459_CR12","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.668131","volume":"9","author":"SFH Neys","year":"2021","unstructured":"Neys SFH, Hendriks RW, Corneth OBJ (2021) Targeting Bruton\u2019s Tyrosine Kinase in Inflammatory and Autoimmune Path ologies. Front Cell Dev Biol 9:668131. https:\/\/doi.org\/10.3389\/fcell.2021.668131","journal-title":"Front Cell Dev Biol"},{"key":"9459_CR13","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.591894","volume":"11","author":"R Chunder","year":"2020","unstructured":"Chunder R, Schropp V, Kuerten S (2020) B cells in multiple sclerosis and virus-induced neuroinflammation. Front Neurol 11:591894. https:\/\/doi.org\/10.3389\/fneur.2020.591894","journal-title":"Front Neurol"},{"issue":"4","key":"9459_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00602","volume":"22","author":"LR Naydovich","year":"2025","unstructured":"Naydovich LR, Orthmann-Murphy JL, Markowitz CE (2025) Beyond relapses: How BTK inhibitors are shaping the future of progress ive MS treatment. Neurotherapeutics 22(4):e00602. https:\/\/doi.org\/10.1016\/j.neurot.2025.e00602","journal-title":"Neurotherapeutics"},{"issue":"10","key":"9459_CR15","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1007\/s40263-022-00951-z","volume":"36","author":"A Geladaris","year":"2022","unstructured":"Geladaris A, Torke S, Weber MS (2022) Bruton\u2019s Tyrosine Kinase Inhibitors in Multiple Sclerosis: Pioneering the Path Towards Treatment of Progression? CNS Drugs 36(10):1019\u201330. https:\/\/doi.org\/10.1007\/s40263-022-00951-z","journal-title":"CNS Drugs"},{"issue":"2","key":"9459_CR16","doi-asserted-by":"publisher","DOI":"10.1111\/cts.13693","volume":"17","author":"M Cabanis","year":"2024","unstructured":"Cabanis M, Nicolas O, Vitse O, Jan C, Brun P, Soubayrol P et al (2024) A phase I trial assessing the safety, pharmacokinetics, cerebrospinal fluid penetrance, and food effect of BTK inhibitor tolebrutinib in healthy volunteers. Clin Transl Sci 17(2):e13693. https:\/\/doi.org\/10.1111\/cts.13693","journal-title":"Clin Transl Sci"},{"issue":"2","key":"9459_CR17","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/cts.13162","volume":"15","author":"TD Owens","year":"2022","unstructured":"Owens TD, Smith PF, Redfern A, Xing Y, Shu J, Karr DE et al (2022) Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168). Clin Transl Sci 15(2):442\u201350. https:\/\/doi.org\/10.1111\/cts.13162","journal-title":"Clin Transl Sci"},{"issue":"9","key":"9459_CR18","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/S1474-4422(21)00237-4","volume":"20","author":"DS Reich","year":"2021","unstructured":"Reich DS, Arnold DL, Vermersch P, Bar-Or A, Fox RJ, Matta A et al (2021) Safety and efficacy of tolebrutinib, an oral brain-penetrant BTK inhib itor, in relapsing multiple sclerosis: a phase 2b, randomised, double- blind, placebo-controlled trial. Lancet Neurol. 20(9):729\u201338. https:\/\/doi.org\/10.1016\/S1474-4422(21)00237-4","journal-title":"Lancet Neurol."},{"issue":"19","key":"9459_CR19","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1056\/NEJMoa2415988","volume":"392","author":"RJ Fox","year":"2025","unstructured":"Fox RJ, Bar-Or A, Traboulsee A, Oreja-Guevara C, Giovannoni G, Vermersch P et al (2025) Tolebrutinib in nonrelapsing secondary progressive multiple sclerosis. N Engl J Med 392(19):1883\u201392. https:\/\/doi.org\/10.1056\/NEJMoa2415988","journal-title":"N Engl J Med"},{"issue":"19","key":"9459_CR20","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1056\/NEJMoa2415985","volume":"392","author":"J Oh","year":"2025","unstructured":"Oh J, Arnold DL, Cree BAC, Ionete C, Kim HJ, Sormani MP et al (2025) Tolebrutinib versus teriflunomide in relapsing multiple sclerosis. N Engl J Med 392(19):1893\u2013904. https:\/\/doi.org\/10.1056\/NEJMoa2415985","journal-title":"N Engl J Med"},{"key":"9459_CR21","doi-asserted-by":"crossref","unstructured":"Higgins J, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al (2019) Cochrane Handbook for Systematic Reviews of Interventions. 2nd ed. Newark: John Wiley & Sons, Incorporated. 1 p. (Wiley Cochrane)","DOI":"10.1002\/9781119536604"},{"key":"9459_CR22","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD et al (2020) The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. https:\/\/doi.org\/10.1136\/bmj.n71","journal-title":"BMJ"},{"key":"9459_CR23","unstructured":"23. The EndNote Team (2013) EndNote. Philadelphia, PA: Clarivate"},{"issue":"1","key":"9459_CR24","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1186\/s12913-014-0579-0","volume":"14","author":"AM Methley","year":"2014","unstructured":"Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S (2014) PICO, PICOS and SPIDER: a comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res 14(1):579. https:\/\/doi.org\/10.1186\/s12913-014-0579-0","journal-title":"BMC Health Serv Res"},{"issue":"1","key":"9459_CR25","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1186\/s13643-016-0384-4","volume":"5","author":"M Ouzzani","year":"2016","unstructured":"Ouzzani M, Hammady H, Fedorowicz Z, Elmagarmid A (2016) Rayyan\u2014a web and mobile app for systematic reviews. Syst Rev 5(1):210. https:\/\/doi.org\/10.1186\/s13643-016-0384-4","journal-title":"Syst Rev"},{"key":"9459_CR26","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovi\u0107 J, Page MJ, Elbers RG, Blencowe NS, Boutron I et al (2019) RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 366:l4898. https:\/\/doi.org\/10.1136\/bmj.l4898","journal-title":"BMJ"},{"key":"9459_CR27","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i4919","volume":"355","author":"JA Sterne","year":"2016","unstructured":"Sterne JA, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M et al (2016) ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ 355:i4919. https:\/\/doi.org\/10.1136\/bmj.i4919","journal-title":"BMJ"},{"issue":"1","key":"9459_CR28","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1002\/jrsm.1411","volume":"12","author":"LA McGuinness","year":"2021","unstructured":"McGuinness LA, Higgins JPT (2021) Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Synth Methods. 12(1):55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411","journal-title":"Res Synth Methods."},{"issue":"7109","key":"9459_CR29","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1136\/bmj.315.7109.629","volume":"315","author":"M Egger","year":"1997","unstructured":"Egger M, Davey Smith G, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315(7109):629\u201334. https:\/\/doi.org\/10.1136\/bmj.315.7109.629","journal-title":"BMJ"},{"issue":"3","key":"9459_CR30","doi-asserted-by":"publisher","DOI":"10.1212\/wn9.0000000000000028","volume":"1","author":"J Oh","year":"2025","unstructured":"Oh J, Fox RJ, Arnold DL, Syed S, Dukovic D, Vargas WS et al (2025) Tolebrutinib phase 2b long-term extension study: two-year safety, MRI, and clinical efficacy outcomes in patients with relapsing multiple sclerosis patients. Neurol Open Access 1(3):e000028. https:\/\/doi.org\/10.1212\/wn9.0000000000000028","journal-title":"Neurol Open Access"},{"issue":"5","key":"9459_CR31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1038\/s41582-023-00800-7","volume":"19","author":"J Kr\u00e4mer","year":"2023","unstructured":"Kr\u00e4mer J, Bar-Or A, Turner TJ, Wiendl H (2023) Bruton tyrosine kinase inhibitors for multiple sclerosis. Nat Rev Neurol 19(5):289\u2013304. https:\/\/doi.org\/10.1038\/s41582-023-00800-7","journal-title":"Nat Rev Neurol"},{"issue":"4","key":"9459_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.neurot.2025.e00601","volume":"22","author":"M Albelo-Mart\u00ednez","year":"2025","unstructured":"Albelo-Mart\u00ednez M, Rizvi S (2025) Progressive multiple sclerosis: Evaluating current therapies and exploring future treatment strategies. Neurotherapeutics 22(4):e00601. https:\/\/doi.org\/10.1016\/j.neurot.2025.e00601","journal-title":"Neurotherapeutics"},{"issue":"2","key":"9459_CR33","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1111\/cts.13162","volume":"15","author":"TD Owens","year":"2022","unstructured":"Owens TD, Smith PF, Redfern A, Xing Y, Shu J, Karr DE et al (2022) Phase 1 clinical trial evaluating safety, exposure and pharmacodynamics of BTK inhibitor tolebrutinib (PRN2246, SAR442168). Clin Transl Sci 15(2):442\u201350. https:\/\/doi.org\/10.1111\/cts.13162","journal-title":"Clin Transl Sci"},{"issue":"04","key":"9459_CR34","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.bnd.2025.06.003","volume":"01","author":"A Abbas","year":"2025","unstructured":"Abbas A, Sabet H, Abouelmagd ME, El-Moslemani M, Ewis DK, Soliman SM et al (2025) Safety and efficacy of Bruton\u2019s tyrosine kinase inhibitors in multiple sclerosis: A systematic review and network meta-analysis of randomized controlled trials. Brain Netw Disord 01(04):230\u20138. https:\/\/doi.org\/10.1016\/j.bnd.2025.06.003","journal-title":"Brain Netw Disord"},{"key":"9459_CR35","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/j.msard.2026.106974","volume":"1","author":"MVS Sobral","year":"2026","unstructured":"Sobral MVS, de Oliveira HM, de Neto APM, Fagundes TP (2026) Efficacy and safety of Bruton\u2019s tyrosine kinase inhibitors compared to Teriflunomide in relapsing multiple sclerosis: a systematic review and meta-analysis. Mult Scler Relat Disord 1:107. https:\/\/doi.org\/10.1016\/j.msard.2026.106974","journal-title":"Mult Scler Relat Disord"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09459-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09459-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-026-09459-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T13:02:52Z","timestamp":1792414972000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-026-09459-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,19]]},"references-count":35,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2026,11]]}},"alternative-id":["9459"],"URL":"https:\/\/doi.org\/10.1007\/s10072-026-09459-6","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,19]]},"assertion":[{"value":"29 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 October 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All the authors confirm that the content of this study has no conflict of interest.","order":3,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"868"}}